Gastric Adenocarcinoma
Oncology·MeSH: Uterine Cervical Neoplasms
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
17 drugs in development·6 companies·18 clinical trials
Drug Pipeline by Phase
Phase 3(7)
Phase 2(4)
Phase 1(5)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| Telisotuzumab Adizutecan | AbbVie Inc. (ABBV) |
Compare drugs
Frequently asked questions
How many drugs are in development for Gastric Adenocarcinoma?
BioSniper tracks 17 drugs in development for Gastric Adenocarcinoma across 6 companies.
How many clinical trials target Gastric Adenocarcinoma?
There are 18 clinical trials targeting Gastric Adenocarcinoma tracked by BioSniper.
What is the prevalence of Gastric Adenocarcinoma?
The estimated prevalence of Gastric Adenocarcinoma is approximately 10.0 per 100,000 population.
Deep-dive into Gastric Adenocarcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis